Bristol-Myers Squibb Co. (BMY): A Technical Analysis

BMY has 36-month beta value of 0.44. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 11 as “hold,” and 2 as “sell.”

The public float for BMY is 2.03B, and currently, short sellers hold a 1.42% ratio of that float. The average trading volume of BMY on June 21, 2024 was 13.88M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

BMY) stock’s latest price update

Bristol-Myers Squibb Co. (NYSE: BMY)’s stock price has soared by 0.78 in relation to previous closing price of 41.04. Nevertheless, the company has seen a loss of -0.29% in its stock price over the last five trading days. reported 2024-06-21 that PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BristolMyersSquibb–European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab.

BMY’s Market Performance

Bristol-Myers Squibb Co. (BMY) has experienced a -0.29% fall in stock performance for the past week, with a -2.15% drop in the past month, and a -19.83% drop in the past quarter. The volatility ratio for the week is 3.12%, and the volatility levels for the past 30 days are at 2.45% for BMY. The simple moving average for the last 20 days is -0.07% for BMY’s stock, with a simple moving average of -18.16% for the last 200 days.

Analysts’ Opinion of BMY

Redburn Atlantic, on the other hand, stated in their research note that they expect to see BMY reach a price target of $54, previously predicting the price at $77. The rating they have provided for BMY stocks is “Neutral” according to the report published on February 06th, 2024.

BofA Securities gave a rating of “Neutral” to BMY, setting the target price at $60 in the report published on January 03rd of the current year.

BMY Trading at -6.16% from the 50-Day Moving Average

After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.69% of loss for the given period.

Volatility was left at 2.45%, however, over the last 30 days, the volatility rate increased by 3.12%, as shares sank -2.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.62% lower at present.

During the last 5 trading sessions, BMY fell by -0.12%, which changed the moving average for the period of 200-days by -31.68% in comparison to the 20-day moving average, which settled at $41.35. In addition, Bristol-Myers Squibb Co. saw -19.39% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $49.78 back on Dec 05 ’23. After this action, BOERNER CHRISTOPHER S. now owns 82,672 shares of Bristol-Myers Squibb Co., valued at $99,560 using the latest closing price.

BOERNER CHRISTOPHER S., the Chief Executive Officer of Bristol-Myers Squibb Co., purchase 3,071 shares at $48.86 during a trade that took place back on Nov 28 ’23, which means that BOERNER CHRISTOPHER S. is holding 79,384 shares at $150,049 based on the most recent closing price.

Stock Fundamentals for BMY

Current profitability levels for the company are sitting at:

  • 0.31 for the present operating margin
  • 0.76 for the gross margin

The net margin for Bristol-Myers Squibb Co. stands at -0.14. The total capital return value is set at 0.19. Equity return is now at value -25.45, with -6.36 for asset returns.

Based on Bristol-Myers Squibb Co. (BMY), the company’s capital structure generated 0.78 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 3.48. The interest coverage ratio of the stock is 10.69.

Currently, EBITDA for the company is 19.18 billion with net debt to EBITDA at 2.76. When we switch over and look at the enterprise to sales, we see a ratio of 2.9. The receivables turnover for the company is 3.24for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.11.


To put it simply, Bristol-Myers Squibb Co. (BMY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts